Aerovate Therapeutics Inc.

Address: 200 Berkeley Street Fl 18

Sponsor Overview

assignment

Specializations

Pulmonary Vascular Disease

Aerovate Therapeutics Inc. demonstrates a concentrated focus on pulmonary arterial hypertension (PAH), a rare and progressive disorder characterized by elevated blood pressure in the pulmonary arteries. The organization's research efforts target patients with established PAH diagnoses who are already receiving background therapy, indicating an emphasis on optimizing treatment outcomes for individuals with ongoing disease management needs.

Pulmonary Arterial Hypertension Management
Pulmonary Vascular Resistance Reduction
Right Ventricular Function Preservation

The therapeutic approach centers on addressing the underlying hemodynamic abnormalities associated with pulmonary hypertension, with particular attention to patients requiring additional therapeutic interventions beyond their current treatment regimens. This focus reflects an understanding of the progressive nature of the condition and the need for enhanced therapeutic strategies in the management of pulmonary vascular remodeling.

Inhaled Therapeutic Delivery Systems

The sponsor's research portfolio emphasizes inhalation therapy as a primary route of drug administration for cardiovascular and pulmonary conditions. This approach leverages the advantages of direct pulmonary delivery, potentially offering improved local drug concentrations while minimizing systemic exposure and associated adverse effects.

Dry Powder Inhalation Technology
Pulmonary Drug Delivery Optimization
Localized Therapeutic Action

The development of inhaled formulations for cardiovascular indications represents a distinctive therapeutic strategy, particularly in the context of pulmonary vascular diseases where targeted delivery to the affected tissue may provide therapeutic advantages. This focus on aerosol-based therapeutics demonstrates innovation in drug delivery methodology for conditions traditionally managed through systemic administration routes.

Exercise Capacity and Functional Status Assessment

Aerovate Therapeutics Inc. incorporates comprehensive evaluation of exercise tolerance and functional capacity as key components of their clinical research programs. The emphasis on six-minute walk distance and other exercise-based assessments reflects recognition of the profound impact that pulmonary vascular diseases have on patients' daily activities and quality of life.

Cardiopulmonary Exercise Testing
Functional Capacity Measurement
Physical Performance Outcomes

This focus on functional endpoints demonstrates commitment to evaluating clinically meaningful improvements that directly affect patients' ability to perform activities of daily living. The integration of exercise-based outcome measures alongside traditional hemodynamic assessments provides a comprehensive evaluation framework for therapeutic efficacy in pulmonary vascular disorders.

Trial Name	Country	Status
Evaluation of AV-101 (Imatinib) Efficacy and Safety in Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Phase 2b/3 Trial	Austria Belgium Czechia France Germany Greece Ireland Italy Latvia Poland Portugal Spain Sweden The Netherlands	Not Recruiting
Long-Term Safety Evaluation of Inhaled Imatinib (AV-101) in Patients with Pulmonary Arterial Hypertension Following Completion of Study AV-101-002	Austria Belgium Czechia France Germany Greece Ireland Italy Latvia Poland Portugal Spain Sweden The Netherlands	Not Recruiting